286 related articles for article (PubMed ID: 19414943)
1. Survey of attitude of physicians on updates in the management of anemia in chronic kidney disease patients.
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2009 May; 20(3):410-6. PubMed ID: 19414943
[TBL] [Abstract][Full Text] [Related]
2. Attitude of physicians in Saudi Arabia towards anemia treatment strategies in patients with chronic kidney disease.
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):65-72. PubMed ID: 17237894
[TBL] [Abstract][Full Text] [Related]
3. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
4. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
5. Attitude of physicians towards the evaluation and treatment of the glomerulonephritis patients.
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2011 Mar; 22(2):252-60. PubMed ID: 21422622
[TBL] [Abstract][Full Text] [Related]
6. Survey of attitude of physicians on updates in the management of anemia in chronic kidney disease patients - an eye-opener.
Binnani PG
Saudi J Kidney Dis Transpl; 2009 Nov; 20(6):1090. PubMed ID: 19861881
[No Abstract] [Full Text] [Related]
7. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
Yoshida T; Hayashi M
Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
[TBL] [Abstract][Full Text] [Related]
8. An economic evaluation of erythropoiesis-stimulating agents in CKD.
Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ
Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
[TBL] [Abstract][Full Text] [Related]
9. The attitude of physicians towards education and rehabilitation of patients on chronic dialysis: a questionnaire survey.
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2006 Dec; 17(4):526-34. PubMed ID: 17186688
[TBL] [Abstract][Full Text] [Related]
10. Hemoglobin maintenance and dosing strategies using intravenous continuous erythropoietin receptor activator in Japanese hemodialysis patients.
Hirai T; Nishizawa Y; Nakazono H; Asai M; Yamashita H; Sasaki A; Yamashita T; Yamashita K; Shigemoto K; Harada S; Mizuiri S
Ther Apher Dial; 2013 Oct; 17(5):498-503. PubMed ID: 24107278
[TBL] [Abstract][Full Text] [Related]
11. Survey of the attitude of physicians towards establishing and maintaining a peritoneal dialysis program.
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2006 Sep; 17(3):355-64. PubMed ID: 16970256
[TBL] [Abstract][Full Text] [Related]
12. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
Nurko S; Spirko R; Law A; Dennis VW
Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
[TBL] [Abstract][Full Text] [Related]
13. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.
Wish JB; Coyne DW
Mayo Clin Proc; 2007 Nov; 82(11):1371-80. PubMed ID: 17976358
[TBL] [Abstract][Full Text] [Related]
14. Attitude of Physicians toward the Use of Erythropoietin in Hemodialysis Patients.
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2005; 16(3):298-305. PubMed ID: 17642796
[TBL] [Abstract][Full Text] [Related]
15. Attitude of physicians towards the follow-up of renal transplant patients: a questionnaire survey in Saudi Arabia.
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2006 Jun; 17(2):159-67. PubMed ID: 16903621
[TBL] [Abstract][Full Text] [Related]
16. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
[TBL] [Abstract][Full Text] [Related]
17. Continuous erythropoietin receptor activator (Mircera) for renal anemia.
McGahan L
Issues Emerg Health Technol; 2008 Feb; (113):1-6. PubMed ID: 18354858
[TBL] [Abstract][Full Text] [Related]
18. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].
Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S
Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529
[TBL] [Abstract][Full Text] [Related]
19. An expert opinion on the current treatment of anemia in patients with kidney disease.
Locatelli F; Del Vecchio L
Expert Opin Pharmacother; 2012 Mar; 13(4):495-503. PubMed ID: 22296648
[TBL] [Abstract][Full Text] [Related]
20. Early responsiveness to continuous erythropoietin receptor activator predicts renal prognosis and is determined by a novel antioxidative marker in non-dialysis chronic kidney disease: a prospective, observational, single-center study.
Ino J; Kasama E; Kodama M; Harada T; Sato K; Eizumi H; Kawashima Y; Nitta K
Clin Exp Nephrol; 2020 Jul; 24(7):590-597. PubMed ID: 32185544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
